Although it has been shown in various studies and meta-analysis that inhibitors of the EGFR/HER2 pathway were associated with higher risks and severity of infections (42–44), the relative contribution of them is often difficult to quantify, as these patients are usually prescribed with other medications, such as corticosteroids, with immunosuppressive effects. The gene discussed is ERBB2; the disease is infection.